Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population

被引:43
作者
Mrozikiewicz, PM [1 ]
Cascorbi, I [1 ]
Brockmoller, J [1 ]
Roots, I [1 ]
机构
[1] HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST KLIN PHARMAKOL,D-10098 BERLIN,GERMANY
关键词
D O I
10.1016/S0009-9236(96)90104-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The frequency of various genotypes of arylamine N-acetyltransferase (NAT2) was investigated in 248 Polish unrelated children. Allele-specific polymerase chain reaction (PCR) was applied for mutation at 341 nucleotide (nt) of NAT2 coding sequence and PCR/restriction fragment length polymorphism for the other mutations. Genotypes coded for slow acetylation in 62.9% (56.6% to 68.9%). The frequency of specific NAT2 alleles was *4(wild-type), 22.0%, *5A(341C, 481T), 5.2%; *5B(341C, 481T, 803G), 33.1%; *5C(341C, 803G), 6.0%; *6A(282T, 590A), 30.0%; *7B(282T, 857A), 3.4%; and *12A(803G), 0.2%. No mutations were found at 191, 434, and 845 nt. By a molecular-genetic procedure, genotypes *4/*6A were confirmed not to mask *6B/*13(590A/282T). *6B and *13 were absent in a composite sample representative of 826 alleles (95% confidence limits, 0% to 0.45%). Five cases of genotype-phenotype discrepancy were sequenced and their mutation allocation confirmed; 21 further genotypes were confirmed by sequencing. This first evaluation of NAT2 genes among a Slavic population should provide a basis for clinical and epidemiologic investigations of NAT2 in the Polish population.
引用
收藏
页码:376 / 382
页数:7
相关论文
共 24 条
[1]   MOLECULAR ANALYSIS OF THE ARYLAMINE N-ACETYLTRANSFERASE POLYMORPHISM IN A SPANISH POPULATION [J].
AGUNDEZ, JAG ;
MARTINEZ, C ;
OLIVERA, M ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :202-209
[2]  
AGUNDEZ JAG, 1995, ONCOLOGY, V52, P7
[3]   GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS [J].
BELL, DA ;
TAYLOR, JA ;
BUTLER, MA ;
STEPHENS, EA ;
WIEST, J ;
BRUBAKER, LH ;
KADLUBAR, FF ;
LUCIER, GW .
CARCINOGENESIS, 1993, 14 (08) :1689-1692
[4]   MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS [J].
BLUM, M ;
DEMIERRE, A ;
GRANT, DM ;
HEIM, M ;
MEYER, UA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) :5237-5241
[5]   ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS [J].
BROCKMOLLER, J ;
ROOTS, I .
CLINICAL PHARMACOKINETICS, 1994, 27 (03) :216-248
[6]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[7]  
CASCORBI I, IN PRESS PHARMACOGEN
[8]  
DROZDZ M, 1987, NEOPLASMA, V34, P481
[9]  
Evans D., 1992, Protein engineering: Proceedings of an AFRC conference on protein engineering in the agricultural and food industry, Selwyn College, Cambridge, 16-17 September 1991., P95
[10]   PREDICTION OF PHENOTYPE FOR ACETYLATION AND FOR DEBRISOQUINE HYDROXYLATION BY DNA-TESTS IN HEALTHY-HUMAN VOLUNTEERS [J].
GRAF, T ;
BROLY, F ;
HOFFMANN, F ;
PROBST, M ;
MEYER, UA ;
HOWALD, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) :399-403